Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies
Journal of Neurochemistry · 2023
DOI: 10.1111/jnc.15909 ↗At a glance
Übersichtsarbeit in Journal of Neurochemistry, 2023. Written by Ruizhi Wang and 2 co-authors. Institution: Departments of Biochemistry and Oncology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Major MEDLINE topics: Neurodegenerative Diseases, Tauopathies, Alzheimer Disease, Pick Disease of the Brain. Cited 19 times so far (Crossref); 115 references. Funded by: NIH HHS, NCI NIH HHS, NIA NIH HHS.
Abstract (original language)
Conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and certain types of frontotemporal dementia (FTD), among which AD is the most prevalent. Extensive post‐translational modifications, especially hyperphosphorylation, and abnormal aggregation of tau protein underlie tauopathy. Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). Peptidyl‐prolyl cis–trans isomerase NIMA‐interacting 1 (Pin1), the only PPIase found to isomerize Pro following phosphorylated Ser or Thr residues, alters phosphorylated tau protein conformation at pT231‐P motif. The cis P‐tau but not trans P‐tau serves as an early driver of multiple neurodegenerative disease, encompassing AD, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis but not trans P‐tau is resistant to protein dephosphorylation and degradation, and also prone to protein aggregation. Cis P‐tau loses its ability to stabilize microtubule, causing and spreading tauopathy mainly in axons, a pathological process called cistauosis. The conformation‐specific monoclonal antibody that targets only the cis P‐tau serves as a very early diagnosis method and a potential treatment of not only conventional tauopathies but also nonconventional tauopathies such as VCID, with clinical trials ongoing. Notably, cis P‐tau antibody is the only clinical‐stage Alzheimer's therapeutic that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. Here we review the identification and pathological consequences of cis pt231‐tau, the role of its regulator Pin1, as well as the clinical implication of cis pt231‐tau conformation‐specific antibody in conventional and nonconventional tauopathies. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departments of Biochemistry and Oncology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
- Robarts Research Institute, Western University, London, Ontario, Canada.
- Department of Pathology and Laboratory Medicine, and Oncology, Western University, London, Ontario, Canada.
- Lawson Health Research Institute, Western University, London, Ontario, Canada.
ORCID profiles: Kun Ping Lu, Xiao Zhen Zhou
Funding
- NIH HHS
- NCI NIH HHS
- NIA NIH HHS
- Canada Foundation for Innovation
- National Institutes of Health
Cite
APA
Wang, R., Lu, K. P., & Zhou, X. Z. (2023). Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15909
Vancouver
Wang R, Lu KP, Zhou XZ. Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies. Journal of Neurochemistry. 2023. doi:10.1111/jnc.15909
BibTeX
@article{Wang2023,
author = {Wang, Ruizhi and Lu, Kun Ping and Zhou, Xiao Zhen},
title = {Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies},
journal = {Journal of Neurochemistry},
year = {2023},
doi = {10.1111/jnc.15909}
}
EUVIMED